- Home
- ANVS vs PSNL Comparison
ANVS vs PSNL Comparison
Compare ANVS & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- PSNL
- Stock Information
- Founded
- ANVS 2008
- PSNL 2011
- Country
- ANVS United States
- PSNL United States
- Employees
- ANVS N/A
- PSNL N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- PSNL Medical Specialities
- Sector
- ANVS Health Care
- PSNL Health Care
- Exchange
- ANVS Nasdaq
- PSNL Nasdaq
- Market Cap
- ANVS 110.4M
- PSNL 321.1M
- IPO Year
- ANVS 2020
- PSNL 2019
- Fundamental
- Price
- ANVS $9.57
- PSNL $5.19
- Analyst Decision
- ANVS Strong Buy
- PSNL Strong Buy
- Analyst Count
- ANVS 6
- PSNL 4
- Target Price
- ANVS $29.67
- PSNL $6.81
- AVG Volume (30 Days)
- ANVS 341.4K
- PSNL 439.4K
- Earning Date
- ANVS 11-06-2024
- PSNL 11-06-2024
- Dividend Yield
- ANVS N/A
- PSNL N/A
- EPS Growth
- ANVS N/A
- PSNL N/A
- EPS
- ANVS N/A
- PSNL N/A
- Revenue
- ANVS N/A
- PSNL $80,027,000.00
- Revenue This Year
- ANVS N/A
- PSNL $10.85
- Revenue Next Year
- ANVS N/A
- PSNL $8.77
- P/E Ratio
- ANVS N/A
- PSNL N/A
- Revenue Growth
- ANVS N/A
- PSNL 19.20
- 52 Week Low
- ANVS $4.53
- PSNL $0.89
- 52 Week High
- ANVS $22.49
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- ANVS 58.70
- PSNL 56.29
- Support Level
- ANVS $9.00
- PSNL $4.54
- Resistance Level
- ANVS $10.54
- PSNL $5.35
- Average True Range (ATR)
- ANVS 0.81
- PSNL 0.30
- MACD
- ANVS 0.12
- PSNL 0.05
- Stochastic Oscillator
- ANVS 74.57
- PSNL 84.71
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.